Niche Focus Target ophthalmology-driven gene therapies for inherited retinal diseases with high unmet need and strong clinical feasibility, presenting clear collaboration opportunities with ophthalmology clinics, specialty centers, and patient advocacy groups.

Strategic Pipeline Leverage AGTC's six ophthalmology programs and two non-ophthalmology programs to pursue partnerships in co-development, licensing, or milestones across rare diseases, expanding reach into alpha-1 antitrypsin deficiency and adrenoleukodystrophy.

IP Advantage Capitalize on a robust IP portfolio and expertise in gene therapy design and delivery to position collaborations around novel vectors, promoters, and expression cassettes with contract research, manufacturing, or know-how licensing.

Clinical-Stage Readiness Engage with clinical-stage opportunities for early access programs, investigator-initiated studies, and strategic funding discussions, aligning with AGTC’s focus on high unmet need indications and potential for do-or-die patient impact.

Strategic Partnerships Propose partnerships with biopharma firms seeking AAV-based gene therapy capabilities, manufacturing expertise, and regulatory navigation support to de-risk programs and accelerate timelines toward pivotal trials and commercialization.